IMUGENE CHART. TA only, page-10979

I think the price action lately got a lot to do with how the big guys are trading IMU and things are explainable if looking into the short sell pattern.





With the recent clinical updates on PD1-Vaxx and CF33/PD-L1, the confirmation on the safety is very great news. However, for cancer treatment, we need something that is safe and also is working. So the updates only answered the first half, but none of them gave any details on the second half, the efficacy on patients, like any size change in tumor or progress/survival status, etc. With the updates on Her-Vaxx, that even seems like air tight now, the least we know is that some patients are happily living and that being one of the reason they can not collect the final date, a really good one. Plus the first quarter of the year, is very riched with conference abstract deadline. I am not surprised with they need to hold up the details a bit longer just for submission to a few of those major events, AACR, ACSO......Particularly Her-Vaxx might have a good chance to go into the 'late breaking' category. Well, a good round of clinical read out is good enough to turn things around for company like IMU.